Merck to purchase biotech Afferent for at least $500 million

Merck & Co. has agreed to purchase biotechnology company Afferent Pharmaceuticals, whose lead drug candidate is being evaluated as a treatment for refractory, chronic cough and idiopathic pulmonary fibrosis with cough.